CRSP — Crispr Therapeutics AG

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates CRSP Bullish with a Setup Score of 25, net conviction 29, actionability 22. How the Setup Score works →

Total Setup Score25
Directional BiasBullish
Net Conviction29
Actionability22 (in range)

Key signals behind this score

About Crispr Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$60.90
Market Cap$5.62B
Float96.3M
Shares Outstanding96.7M
P/E (Forward)23.36
Price/Sales (TTM)419.64
vs. Analyst Target+43.8% to analyst PT
Operating Margin (TTM)-1127.55%
Revenue (TTM)$13.4M
Dividend RateNone
Analyst Target Price$87.56 (28 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $719,000 -$349M -$269M -$345M
2021 $913M $378M $913M $391M
2022 $436,000 -$650M -$110M -$649M
2023 $370M -$154M $240M -$131M
2024 $35.0M -$366M -$75.3M -$343M
2025 $3.5M -$582M -$229M -$558M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $889,000 -$106M
Dec 2025 $864,000 -$131M
Mar 2026 $1.5M -$123M
Jun 2026 $10.2M -$91.2M

Ownership & Float

Insider Ownership5.9%
Institutional Ownership77.9%
Short Float19.5%
% of All Funds Holding5.89%
Number of Funds Holding518

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$53.81Near-term / short-term trend
Weekly40-Week SMA$53.00Medium-term trend
Weekly80-Week SMA$51.71Cyclical trend (business cycle)
Weekly200-Week SMA$52.93Secular trend (multi-year)
Monthly10-Month SMA$53.55Near-term monthly trend
Monthly20-Month SMA$50.78Medium-term monthly trend
Monthly40-Month SMA$53.04Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$36.80 support 1.69x 13 months ago

Historical Earnings Reactions (40 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.39% 0.19% 55.00% 5.47% -8.88%
1 Day 1.70% 0.93% 60.00% 13.57% -8.70%
1 Week 1.39% 0.57% 52.50% 27.28% -14.39%
2 Weeks 1.61% -0.09% 50.00% 33.87% -24.20%
1 Month 2.06% -1.03% 46.15% 59.75% -35.93%

Next earnings: October 22, 2026 (56 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan7.3%60.0%10
Feb9.8%70.0%10
Mar-10.5%20.0%10
Apr0.6%70.0%10
May8.7%60.0%10
Jun11.0%70.0%10
Jul2.4%70.0%10
Aug-1.2%44.4%9
Sep-5.8%22.2%9
Oct-4.5%33.3%9
Nov17.3%70.0%10
Dec-6.5%20.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.44% 54.0% 463
Tuesday 0.21% 48.7% 509
Wednesday 0.06% 49.2% 506
Thursday -0.05% 47.8% 498
Friday 0.05% 47.5% 497

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 77.9%

Insider Transactions — Smart Summary

Total insider ownership: 5.9%

12-Month Insider Activity Summary

Total Filings20
Net Value-$13.9M
Net Shares Change22,314
% of Float0.0%
C-Suite Filings20
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Kulkarni Samarth Chief Executive Officer -$9.1M 3 N/A
Prasad Raju Chief Financial Officer -$1.2M 3 N/A
Patel Naimish Chief Medical Officer -$312,892.64 3 1 buy
KASINGER JAMES R. General Counsel and Secretary -$148,853.96 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-12 – 2026-03-24 9 4 -$2.8M 9 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-27 Patel Naimish Chief Medical Officer +$49,703.68 Transaction at $32.96, now +84.8%
2026-06-01 Patel Naimish Chief Medical Officer -$210,577.32 Transaction at $55.62, now +9.5%
2026-03-24 Prasad Raju Chief Financial Officer -$173,460.24 Transaction at $46.78, now +30.2%
2026-03-17 Prasad Raju Chief Financial Officer -$476,277.94 Transaction at $48.26, now +26.2%
2026-03-17 Patel Naimish Chief Medical Officer -$152,019 Transaction at $48.26, now +26.2%
2026-01-22 Kulkarni Samarth Chief Executive Officer -$5.2M Transaction at $57.40, now +6.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Crispr Therapeutics AG (CRSP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CRSP on Trend Edge →